Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Amir Heshmatpour purchased 9,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was bought at an average price of $5.54 per share, with a total value of $49,860.00. Following the acquisition, the chief executive officer directly owned 3,096,000 shares in the company, valued at approximately $17,151,840. This represents a 0.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Neonc Technologies Trading Up 12.6%
Shares of NASDAQ NTHI opened at $5.53 on Wednesday. Neonc Technologies Holdings, Inc. has a 52 week low of $3.01 and a 52 week high of $12.99. The firm has a 50-day moving average price of $4.14 and a 200 day moving average price of $6.02.
Neonc Technologies (NASDAQ:NTHI - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).
Key Headlines Impacting Neonc Technologies
Here are the key news stories impacting Neonc Technologies this week:
- Positive Sentiment: NEO100 reached a Phase 2a endpoint: The company reported that NEO100 produced positive Phase 2a results in recurrent IDH1-mutant high-grade glioma, including extended survival. The update strengthens the investment case for NeOnc’s central-nervous-system drug platform and could support further development or partnership interest. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
- Positive Sentiment: Repeated CEO insider buying is supporting sentiment: Heshmatpour purchased 12,000 shares on August 14 for approximately $45,480, 3,000 shares on August 17 for $13,110, and another 9,000 shares on August 18 for $49,860. The purchases increased his already substantial ownership and signal management confidence, although insider buying does not guarantee clinical or financial success. SEC Form 4 Filing
- Neutral Sentiment: Analyst views remain mixed: Several firms maintain Buy ratings and price targets ranging from $13 to $20, while other services have issued Hold or Sell opinions. The reported consensus rating is Hold, highlighting both the substantial upside analysts see and the risks surrounding this early-stage biotech.
- Neutral Sentiment: Shareholder actions expand financing capacity: Stockholders elected directors and approved an expansion of the equity plan by 1 million shares. The authorization may provide capital for development, but it also creates potential future dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve Equity Plan Expansion
- Negative Sentiment: Recent earnings results were weak: NeOnc reported a quarterly loss of $0.58 per share, significantly wider than the $0.12 loss analysts expected. The miss underscores the company’s ongoing cash-burn and execution risks while its clinical programs remain in development.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. HighPoint Advisor Group LLC boosted its stake in Neonc Technologies by 20.5% in the 4th quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company's stock worth $9,466,000 after buying an additional 194,408 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Neonc Technologies by 5.0% during the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company's stock valued at $1,650,000 after acquiring an additional 11,108 shares during the last quarter. Westmount Partners LLC lifted its holdings in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock worth $893,000 after acquiring an additional 153,858 shares during the period. BlackRock Inc. purchased a new position in shares of Neonc Technologies during the 2nd quarter worth about $815,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Neonc Technologies in the third quarter worth approximately $1,279,000.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. BTIG Research restated a "buy" rating and issued a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, May 26th. Weiss Ratings cut shares of Neonc Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Neonc Technologies from a "hold" rating to a "sell" rating in a research note on Saturday. Alliance Global Partners initiated coverage on Neonc Technologies in a research report on Tuesday, May 19th. They set a "buy" rating and a $13.00 price objective for the company. Finally, Maxim Group began coverage on Neonc Technologies in a research note on Monday, May 18th. They issued a "buy" rating and a $20.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $16.00.
Get Our Latest Stock Report on Neonc Technologies
Neonc Technologies Company Profile
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
